Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "4-methylpiperidine" patented technology

Method for synthesizing citric acid tofacitinib

The invention discloses an efficient and safe method for synthesizing citric acid tofacitinib. N-[(3R,4R)-1-benzyl-4-methylpiperidine-3-base]-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine is used as the raw material, Pd / C and HCOOH reduction debenzylation is conducted, condensation is conducted under the catalysis of an EDCI or EDCI, HOBT and triethylamine compound system with cyanoacetic acid, and salifying is conducted with citric acid in acetone to obtain citric acid tofacitinib. By the adoption of the synthesis method, potential safety hazards caused by hydrogen and ammonium formate are avoided, debenzylation reaction and amidation are thorough, no side reaction is caused basically, reaction time is shortened greatly, yield is high, aftertreatment is easy, and citric acid tofacitinib can be prepared efficiently and safely.
Owner:ZHEJIANG LEPU PHARMA CO LTD

Preparation method of tofacitinib citrate

The invention relates to a method for preparing tofacitinib citrate. The method comprises the following steps: by taking N-methyl-N-((3R, 4R)-1-benzyl-4-methylpiperidine-3-yl)-7H-pyrrolo (2, 3-d) pyrimidin-4-amine as a raw material, performing hydrogenation to remove an amino protecting group, performing amidation reaction and salt-forming reaction and finally drying to obtain tofacitinib citrate. In the preparation process, after-treatment is not required, the separation of a target intermediate is not required, and only reactants need to be added sequentially. The preparation method of tofacitinib citrate provided by the invention has the advantages of simplicity in operation, high yield, mild conditions and the like, and is suitable for industrial production.
Owner:SUNSHINE LAKE PHARM CO LTD

Preparation method of tofacitinib citrate

The invention relates to a preparation method of tofacitinib citrate, in particular to high-yield synthesis of tofacitinib citrate. The tofacitinib citrate is synthesized from raw materials including4-chloro-7-pyrrolo[2,3-d]pyrimidine, (BOC)2O, (3R,4R)-(1-benzyl-4-methylpiperidine-3-yl)methylamine-L-di-p-toluoyl tartrate, Pd / C, cyanoacetic acid and citric acid through six steps including an aminoprotection reaction, an amination reaction, a debenzylation reaction, a condensation reaction, a deprotection reaction and a salt forming reaction. The synthesis route provides the preparation methodof tofacitinib citrate, and the preparation method is high in yield, low in cost, easy to operate and suitable for industrialization.
Owner:南京法恩化学有限公司

Synthesis method for tofacitinib

The invention relates to a synthesis method for tofacitinib serving as a JAK inhibitor. According to the method, the tofacitinib is prepared by taking (4-picoline-3-yl)methyl carbamate as a raw material, and performing catalytic hydrogenation, benzyl protection, reduction, salification, separation, deprotection and amidation salification. The method specifically comprises the following steps: (1) performing catalytic hydrogenation and reduction on (4-picoline-3-yl)methyl carbamate in sulfuric acid and Pd / C; (2) reacting cis-(4-picoline-3-yl)methyl carbamate and benzyl chloride to obtain cis-(1-benzyl-4-methylpiperidine-3-yl)methyl carbamate; (3) performing HOBT catalytic condensation on N-[(3R,4R)-4-methylpiperidine-3-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine and cyanoacetic acid to obtain tofacitinib free alkali. The preparation method provided by the invention has easily obtained raw materials, mild reaction conditions, easiness and convenience in operation and high yield, and is suitable for industrial production.
Owner:济南扬诺生物科技有限公司

Method for preparing 4-methylpiperidine-2-carboxylate hydrochloride

The invention relates to a method for preparing 4-methylpiperidine-2-carboxylate hydrochloride which is an intermediate of argatroban active precursor (2R, 4R)-4-methylpiperidine-2-carboxylic acid ethyl ester. 4-methylpiperidine-2-carboxylic acid ethyl ester is adopted as a raw material, phosphomolybdic acid is used as a catalyst, oxidizing is performed to obtain 4-methylpiperidine-2-carboxylic acid ethyl ester nitrogen oxide, methanol or ethanol is taken as a solvent, and 4-methylpiperidine-2-carboxylate hydrochloride is produced through reduction reaction. The method is simple to operate and has moderate conditions; phosphomolybdic acid is adopted to increase the activity of an oxidizing agent of hydrogen peroxide, the usage of the oxidizing agent is reduced, and the reaction yield is increased; the purification is convenient, the product quality is excellent, and good safety is obtained; and pollution is reduced, and industrial production is benefited.
Owner:CHANGSHAN BIOCHEM PHARM JIANGSU CO LTD

Asymmetric synthesis method of nitrogen protected (3R,4R)-3-methylamino-4-methylpiperidine, and relevant intermediate and raw material preparation method

The invention relates to a preparation method of nitrogen protected (3R,4R)-3-methylamino-4-methylpiperidine (I). The method comprises the following steps: carrying out a reductive amination reaction on a compound of formula (III) and (R)-1-phenylethylamine to obtain a compound of formula (II), removing chiral prosthetic groups from the compound of formula (II), and adding a methyl group to the amino group of the compound of formula (II) in order to obtain nitrogen protected (3R,4R)-3-methylamino-4-methylpiperidine (I), wherein R in each of the formula (I), the formula (II) and the formula (III) is an amino protection group or hydrogen, and the amino protection group can be C1-4 alkoxycarbonyl, benzyloxycarbonyl or benzyl groups which can be removed through hydrolysis or hydrogenation. The asymmetric synthesis method of nitrogen protected (3R,4R)-3-methylamino-4-methylpiperidine (I) has the advantages of reasonable technology, concise route, obtaining of the required product in a high ee value manner by constructing two chiral centers through chiral induced one-step reductive amination, cheap raw materials, and no waste isomer emission, and is suitable for large-scale industrialized production.
Owner:SHANGHAI PUYI CHEM CO LTD

Preparing method of (2R,4R)-4-methylpiperidine-2-ethyl formate compound

The invention relates to a preparing method of a (2R,4R)-4-methylpiperidine-2-ethyl formate compound. The method comprises the following steps of 1, regarding 4-methyl-2-cyanopiperidine as an initialraw material to be subjected to a hydrolysis reaction through hydrochloric acid to obtain 4-methyl-2-piperidinecarboxylicacid hydrochloride; 2, using ethyl alcohol to esterify 4-methyl-2-piperidinecarboxylicacid hydrochloride to obtain 4-methyl-2-ethyl nipecotate hydrochloride; 3, adding a mixed solvent of methyl tertiary butyl ether and ethyl alcohol, reacting the mixed liquid for pulping, filtering to remove cis-form 4-methyl-2-ethyl nipecotate hydrochloride solid, and collecting mother liquor to obtain anti-form 4-methyl-2-ethyl nipecotate hydrochloride; 4, using L-tartaric acid to split anti-form 4-methyl-2-ethyl nipecotate to obtain the target product (2R,4R)-4-methylpiperidine-2-ethyl formate.
Owner:BEIJING VOBAN PHARMA TECH CO LTD

Chinlon 6 for spinning and manufacturing method thereof

The invention relates to chinlon 6 for spinning. The chinlon 6 is prepared from the following raw materials in parts by mass: 96 to 98 parts of caprolactam, 2 to 4 parts of desalted water, 0.28 to 0.3 part of molecular weight controlling agents and 0.05 to 0.15 part of thermal stabilizers, wherein the molecular weight controlling agents are any one kind of materials from terephthalic acid, m-phthalic acid and 1.4-phenylenediacetic acid; the thermal stabilizers are 4-amino-2,2,6,6-4 methyl piperidine and N,N'-bis(2,2,6,6- tetramethyl-4 piperidyl)-1,3-benzenedicarboxamide.
Owner:FUJIAN ZHONGJIN NEW MATERIALS

Preparing method of 1-triazole-2-butanol derivative

The invention relates to a preparing method of a 1-triazole-2-butanol derivative. The preparing method comprises the steps of making 4-methylpiperidine addition salt react with (2R,3S)-2-(2,4-di-fluorophenyl)-3-methyl-2-[(1H-1,2,4-traizole-1-radical)methyl]oxirane in a solvent in the presence of lithium halide and / or magnesium halide and alkaline to generate the 1-triazole-2-butanol derivative. The reaction is complete, the selectivity is high, and the product of the 1-triazole-2-butanol derivative of which the purity is larger than 99% can be obtained through simple aftertreatment. Besides, the yield is high no matter which form of 4-methylpiperidine addition salt is adopted as raw materials.
Owner:SUZHOU VIGONVITA LIFE SCIENCES CO LTD

Synthetic method of piperonal

The invention relates to the technical field of the medical intermediate fine chemical industry and in particular relates to a synthetic method of piperonal. The synthetic method comprises the following steps: 1 uniformly mixing benzodioxole, formaldehyde with concentration of 40% and a primary catalyst dodecyl trimethyl ammonium bromide with a solvent, then adding hydrochloric acid with concentration of 35-37% and standing for layering after reaction, thus obtaining a piperonyl chloride solution, wherein the solvent is trichloromethane, tetrachloromethane or methylbenzene; 2 preparing a sodium bicarbonate or sodium carbonate water solution with concentration less than or equal to that of a saturated solution, adding the sodium bicarbonate or sodium carbonate water solution to the piperonyl chloride solution and reacting to obtain a piperonyl alcohol solution; 3 introducing air into the piperonyl alcohol solution to oxidize the piperonyl alcohol solution to generate a piperonal solution by using both ferric nitrate and 4-hydroxy-2,2,4,4-methylpiperidine nitroxyl free radical as final catalysts. The synthetic method provided by the invention has the advantages of accessible raw materials, mild reaction conditions, stable and high yield, few byproducts and low cost.
Owner:李东风

Preparation method of argatroban intermediate

The invention relates to a preparation method of argatroban intermediate (2R,4R)-ethyl-1-((S)-2-(tert-butoxy amido)-5-(3-nitroguanidine)valery)-4-methylpiperidine-2-ethyl carboxylate. The method comprises the following steps: enabling NG-nitro-N2-t-Boc-L-arginine and (2R,4R)-4-methyl-2-ethyl nipecotate to perform condensation reaction in the presence of a condensing agent selected from 1-ethyl-3-(3-dimethylamine propyl)carbodiimide hydrochloride, N,N-diisopropyl carbodiimide and N,N'-carbonyl diimidazole and an aprotic solvent to generate the argatroban intermediate. The raw material for the method is wide in source, cheap and easily-available; the method is mild in reaction condition, short in step, simple in operation, easy to purify the product, low in production cost and environment-friendly, not only suitable for laboratory synthesis, but also suitable for large-scale industrial production.
Owner:SHANGHAI SYNCORES TECH INC

Synthesis method of (3R, 4R)-N-PG-4-methyl-3-methylaminopiperidine

The invention relates to a synthesis method of (3R, 4R)-N-PG-4-methyl-3-methylaminopiperidine, the structural formula of which is as the following, wherein PG is an amino protecting group. The synthesis steps comprise: 1) cyclization: putting 2-butenal, N-PG-2-nitroethylamine, a catalyst and an organic acid into a reaction medium to react at a temperature ranging from -10 to 50DEG C for 0.5-8h; at the end of the reaction, adding an acid into the system to undergo dehydration, and letting the substances further react for 1-5h at 10-50DEG C so as to obtain (3R, 4R)-N-PG-4-methyl-3-nitro-3, 4-dihydropyridine, with the structure of the catalyst shown as the following; 2) subjecting (3R, 4R)-N-PG-4-methyl-3-nitro-3, 4-dihydropyridine to catalytic hydrogenation reduction so as to obtain (3R, 4R)-N-PG-3-amino-4-methylpiperidine; and 3) subjecting the (3R, 4R)-N-PG-3-amino-4-methylpiperidine to a methylation reaction so as to generate the target product.
Owner:LUOYANG NORMAL UNIV

Spinning polyamide 6 and manufacture method thereof

Spinning polyamide 6 comprises the following raw materials, by mass part, 96-98 parts of caprolactam, 2-4 parts of desalted water, 0.28-0.3 part of a molecular weight control agent, and 0.05-0.15 part of a heat stabilizer, wherein the molecular weight control agent is any two of adipic acid, terephthalic acid and acetic acid, and the heat stabilizer is any one of 4-amino-2,2,6,6-4-methyl piperidine and N,N'-di(2,2,6,6-tetramethyl-4-piperidyl)-1,3-benzenedicarboxamide.
Owner:FUJIAN ZHONGJIN NEW MATERIALS

Preparation process of Xeljanz intermediate

The invention belongs to the technical field of pharmaceutical synthesis, in particular to a preparation process of a Xeljanz intermediate. The preparation process comprises the following steps: 1) adding ethyl cyanoacetate into n-butyl alcohol, and uniformly stirring; 2) dropwise adding DBU into a solution prepared in the step 1) at a temperature of or below 30 DEG C; 3) adding N-methyl-N-((3R,4R)-4-methylpiperidine-3-yl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine into a solution prepared in the step 2) in batches for reacting; 4) dropwise adding water into a system reacting completely in the step 3), stirring, filtering and washing to obtain the Xeljanz intermediate, namely, (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyridine-4-amino)-beta-oxy-1-piperidine propionitrile. The intermediate prepared by the invention has higher yield and purity, and the decrease of the purity of the intermediate in expanded production is less.
Owner:国药集团容生制药有限公司 +1

Preparation method for Xeljanz related substance

The invention discloses a preparation method for a Xeljanz related substance. The preparation method is characterized by comprising the following steps: with N-methyl-N-((3R,4R)-4-methylpiperidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine hydrochloride and acetaldehyde as starting materials, preparing N-((3R,4R)-1-ethyl-4-methylpiperidine-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine under the action of a reducing agent, and carrying out salification so as to obtain the Xeljanz related substance namely N-((3R,4R)-1-ethyl-4-methylpiperidine-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine hydrochloride as shown in a formula (I) which is described in the specification.
Owner:JIANGSU QINGJIANG PHARMA

Synthesis method of N-benzyl-4-methylpiperidine-3-one hydrochloride

The invention discloses a synthesis method of N-benzyl-4-methylpiperidine-3-one hydrochloride. The synthesis method includes the steps of: a) with N-benzyl glycine ethyl ester as a raw material, performing a condensation reaction to the raw material with 2-methyl-4-halogenated ethyl acetate; and b) after the reaction is finished, performing an intramolecular cyclization reaction and finally performing hydrolytic decarboxylation to prepare the product. Compared with methods reported in references, the method establishes a novel synthesis route which is short in process, is novel in technology, employs low-cost raw materials and simple process operations, has good product quality and high total yield, and is suitable for industrial production.
Owner:CHONGQING WORLD HAORUI PHARM CHEM

Tofacitinib citrate impurity as well as analysis method and application thereof

The invention provides a novel impurity in tofacitinib citrate, namely, 3-((3R,4R)-3-((7-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-4-yl)(methyl)amino)-4-methylpiperidine-1-yl)-3-oxopropionitrile. The preparation method of the compound is simple to operate, the obtained product is high in yield and purity, the invention further provides an analysis method of the compound, the method is sensitive, rapid and good in specificity, and the compound can be used as a reference substance for researching impurities in tofacitinib citrate raw materials and preparations, so that the product quality is effectively controlled.
Owner:CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD

Method for preparingtofacitinib citrate

The invention provides a method for preparing tofacitinib citrate. The method for preparing tofacitinib citratecomprises the following steps that1, N-methyl-N-((3R,4R)-4-methylpiperidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine and ethyl cyanoacetate are added into methyl alcohol for condensation reaction to prepare and obtain 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile;and 2,3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrileis added to a mixed solvent and subjected to 80+ / -5 DEG reflux, additionally, citric acid is dissolved in the mixed solvent and then added slowly to a reflux system forsalt forming reaction, cooling, filtration, washing, and drying to obtain 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile citrate. According to the method for preparing tofacitinib citrate, operation isconvenient, time consumption isless, the yield rate is high, product impurity is low,and purity is good.
Owner:CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD

Preparation method of (3R,4R)-(1-benzyl-4-methylpiperidine-3-yl)methylamine-L-di-p-toluoyltartaric acid salt

The invention discloses a preparation method of (3R,4R)-(1-benzyl-4-methylpiperidine-3-yl)methylamine-L-di-p-toluoyltartaric acid salt prepared from the following reaction steps shown in the description. The preparation method of (3R,4R)-(1-benzyl-4-methylpiperidine-3-yl)methylamine-L-di-p-toluoyltartaric acid salt has the following advantages that the process is novel in design, extremely dangerous chemicals (such as lithium aluminum hydride) are not required to be used, a folding condensation process is adopted, and the total yield is high; more importantly, the starting materials are cheap and easy to obtain, and the cost is low; and the maneuverability is high, and industrialization is easy.
Owner:刘卫国
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products